756 Effects of Gluten-Free (GFD) and Gluten-Containing Diet (GCD) on Gastrointestinal and Colonic Transit, Permeability and Small Bowel Inflammation in Irritable Bowel Syndrome With Diarrhea (IBS-D): A Randomized Study

Genetic variations in metabolism of endocannabinoids and in CNR1 (gene for cannabinoid 1 receptor) are associated with symptom phenotype, colonic transit, and left colon motility in irritable bowel syndrome (IBS). Our aim was to evaluate associations between two variations in CNR1 genotype (rs806378 and [AAT]n triplets) with symptom phenotype, small bowel and colonic transit, and rectal sensations in 455 patients with IBS and 228 healthy controls. Small bowel and colonic transit were measured by scintigraphy, rectal sensation by isobaric distensions. Associations with genotype were assessed by χ2 test (symptom phenotype) and ANCOVA (quantitative traits) based on a dominant genetic model. Significant association of CNR1 rs806378 (but not CNR1 [AAT]n) genotype and symptom phenotype was observed (χ2 P = 0.028). There was significant association of CNR1 rs806378 ( P = 0.014; CC vs. CT/TT) with colonic transit in IBS-diarrhea (IBS-D) group; the TT group had the fastest colonic transit at 24 and 48 h. There was significant overall association of CNR1 rs806378 with sensation rating of gas ( P = 0.025), but not pain; the strongest associations for gas ratings were in IBS-D ( P = 0.002) and IBS-alternating ( P = 0.025) subgroups. For CNR1 (AAT)n, gene-by-phenotype interactions were observed for colonic transit at 24 ( P = 0.06) and 48 h ( P = 0.002) and gas ( P = 0.046, highest for IBS-D, P = 0.034), but not pain sensation; the strongest association with transit was in controls, not in IBS. These data support the hypothesis that cannabinoid receptors may play a role in control of colonic transit and sensation in humans and deserve further study as potential mediators or therapeutic targets in lower functional gastrointestinal disorders.

Download Full-text

Gluten-free diet in the management of patients with irritable bowel syndrome, fibromyalgia and lymphocytic enteritis

Arthritis Research & Therapy ◽

10.1186/s13075-014-0505-1 ◽

2014 ◽

Vol 16 (6) ◽

Author(s):

Umberto Volta

Keyword(s):

Irritable Bowel Syndrome ◽

Gluten Free Diet ◽

Gluten Free ◽

Irritable Bowel

Download Full-text

Prevalence and risk factors of irritable bowel syndrome in Irkutsk

Medical Council ◽

10.21518/2079-701x-2021-15-152-157 ◽

2021 ◽

pp. 152-157

Author(s):

V. V. Tsukanov ◽

A. V. Vasyutin ◽

E. V. Onuchina ◽

I. L. Petrun’ko ◽

E. V. Kasparov ◽

...

Keyword(s):

Risk Factors ◽

Irritable Bowel Syndrome ◽

Randomized Study ◽

Careful Attention ◽

Female Sex ◽

The World ◽

Undifferentiated Type ◽

Irritable Bowel ◽

New Criteria ◽

Rome Iv

Introduction. The study of the problem of irritable bowel syndrome (IBS) in recent years has been very dynamic. In the Rome IV criteria, new criteria for the diagnosis of this pathology were proposed. Along with the existence of ethnic and geographic differences, this has led to an increase in the activity of studies on the prevalence of IBS.Aim. To study the prevalence and risk factors of irritable bowel syndrome in Irkutsk.Materials and methods. A single-stage observational non-randomized study was performed on the basis of three medical institutions in Irkutsk. Interviewing and clinical examination were performed in 1 529 people: 724 men and 805 women, average age 51.0 years. The questionnaire contained questions to determine the presence of alarm symptoms. The diagnosis of IBS was based on the Rome IV criteria. IBS with a predominance of diarrhea, IBS with a predominance of constipation and mixed and undifferentiated IBS were distinguished. Taking into account the position of the Rome IV criteria and the recommendations of the American College of Gastroenterology (2021), we used a positive diagnosis of IBS in our study and did not perform an instrumental examination of patients.Results. The prevalence of IBS was 12.3%. Among the subtypes of IBS, IBS prevailed with a predominance of constipation (prevalence 5.7%) and IBS of mixed and undifferentiated type (prevalence 4.6%). Risk factors for IBS were female sex (OR = 0.73; CI 0.53-0.99; p = 0.05), age over 50 years (OR = 0.66; CI 0.48-0.90; p = 0.01) and obesity (OR = 0.46; CI 0.31-0.69; p < 0.001). Risk factors for IBS with a predominance of constipation were female sex (OR = 0.46; CI 0.29-0.73; p = 0.001), age over 50 years (OR = 0.46; CI 0.29-0.73; p = 0.001) and obesity (OR = 0.41; CI 0.23-0.72; p = 0.002).Conclusions. In general, our results are consistent with data from other regions of the world. It should be emphasized that the prevalence of IBS in Irkutsk is quite high, which requires careful attention to this problem.

Download Full-text

Effect of gluten-free diet and co-morbidity of irritable bowel syndrome-type symptoms on health-related quality of life in adult coeliac patients

Digestive and Liver Disease ◽

10.1016/j.dld.2007.05.017 ◽

2007 ◽

Vol 39 (9) ◽

pp. 824-828 ◽

Cited By ~ 29

Author(s):

P. Usai ◽

R. Manca ◽

R. Cuomo ◽

M.A. Lai ◽

M.F. Boi

Keyword(s):

Quality Of Life ◽

Irritable Bowel Syndrome ◽

Syndrome Type ◽

Gluten Free ◽

Health Related Quality ◽

Co Morbidity ◽

Related Quality ◽

Health Related ◽

Irritable Bowel

Download Full-text

Genetic Susceptibility to Inflammation is Associated With Colonic Transit and Other Intermediate Phenotypes in Irritable Bowel Syndrome

Gastroenterology ◽

10.1016/s0016-5085(11)60618-5 ◽

2011 ◽

Vol 140 (5) ◽

pp. S-152 ◽

Cited By ~ 2

Author(s):

Michael Camilleri ◽

Paula Carlson ◽

Sanna McKinzie ◽

Marco Zucchelli ◽

Mauro D'Amato ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Genetic Susceptibility ◽

Colonic Transit ◽

Intermediate Phenotypes ◽

Irritable Bowel

Download Full-text

2103 Fecal bile acids, fecal short-chain fatty acids, and the intestinal microbiota in patients with irritable bowel syndrome (IBS) and control volunteers

Journal of Clinical and Translational Science ◽

10.1017/cts.2018.75 ◽

2018 ◽

Vol 2 (S1) ◽

pp. 12-13

Author(s):

Andrea Shin ◽

David Nelson ◽

John Wo ◽

Michael Camilleri ◽

Toyia James-Stevenson ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Bile Acid ◽

Organic Acids ◽

Gastrointestinal Transit ◽

Fecal Microbiota ◽

Colonic Transit ◽

Short Chain ◽

Fecal Excretion ◽

Acid Excretion ◽

Irritable Bowel

OBJECTIVES/SPECIFIC AIMS: Objectives and goals of this study will be to: (1) compare fecal microbiota and fecal organic acids in irritable bowel syndrome (IBS) patients and controls and (2) investigate the association between colonic transit and fecal microbiota in IBS patients and controls. METHODS/STUDY POPULATION: We propose an investigation of fecal organic acids, colonic transit and fecal microbiota in 36 IBS patients and 18 healthy controls. The target population will be adults ages 18–65 years meeting Rome IV criteria for IBS (both diarrhea- and constipation-predominant, IBS-D and IBS-C) and asymptomatic controls. Exclusion criteria are: (a) history of microscopic colitis, inflammatory bowel disease, celiac disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled thyroid disease, liver disease, or elevated AST/ALT>2.0× the upper limit of normal, (b) prior radiation therapy of the abdomen or abdominal surgeries with the exception of appendectomy or cholecystectomy >6 months before study initiation, (c) ingestion of prescription, over the counter, or herbal medications affecting gastrointestinal transit or study interpretation within 6 months of study initiation for controls or within 2 days before study initiation for IBS patients, (d) pregnant females, (e) antibiotic usage within 3 months before study participation, (f) prebiotic or probiotic usage within the 2 weeks before study initiation, (g) tobacco users. Primary outcomes will be fecal bile acid excretion and profile, short-chain fatty acid excretion and profile, colonic transit, and fecal microbiota. Secondary outcomes will be stool characteristics based on responses to validated bowel diaries. Stool samples will be collected from participants during the last 2 days of a 4-day 100 g fat diet and split into 3 samples for fecal microbiota, SCFA, and bile acid analysis and frozen. Frozen aliquots will be shipped to the Metabolite Profiling Facility at Purdue University and the Mayo Clinic Department of Laboratory Medicine and Pathology for SCFA and bile acid measurements, respectively. Analysis of fecal microbiota will be performed in the research laboratory of Dr David Nelson in collaboration with bioinformatics expertise affiliated with the Nelson lab. Colonic transit time will be measured with the previously validated method using radio-opaque markers. Generalized linear models will be used as the analysis framework for comparing study endpoints among groups. RESULTS/ANTICIPATED RESULTS: This study seeks to examine the innovative concept that specific microbial signatures are associated with increased fecal excretion of organic acids to provide unique insights on a potential mechanistic link between altered intraluminal organic acids and fecal microbiota. DISCUSSION/SIGNIFICANCE OF IMPACT: Results may lead to development of targets for novel therapies and diagnostic biomarkers for IBS, emphasizing the role of the fecal metabolome.

Download Full-text

Irritable Bowel Syndrome and Gluten-Related Disorders

Nutrients ◽

10.3390/nu12041117 ◽

2020 ◽

Vol 12 (4) ◽

pp. 1117 ◽

Cited By ~ 3

Author(s):

Paolo Usai-Satta ◽

Gabrio Bassotti ◽

Massimo Bellini ◽

Francesco Oppia ◽

Mariantonia Lai ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Celiac Disease ◽

The Other ◽

Gluten Free Diet ◽

Gluten Free ◽

Gut Permeability ◽

Online Search ◽

Systematic Screening ◽

Wheat Sensitivity ◽

Irritable Bowel

Background: Irritable bowel syndrome (IBS) is frequently associated with celiac disease (CD) and nonceliac gluten/wheat sensitivity (NCGS/NCWS), but epidemiological and pathophysiological aspects are still unclear. Furthermore, a gluten-free diet (GFD) can positively influence IBS symptoms. Methods: A comprehensive online search for IBS related to CD, NCGS and GFD was made using the Pubmed, Medline and Cochrane databases. Results: Although a systematic screening for CD in IBS is not recommended, CD prevalence can be increased in diarrhea-predominant IBS patients. On the other hand, IBS symptoms can be persistent in treated CD patients, and their prevalence tends to decrease on a GFD. IBS symptoms may overlap and be similar to those associated to nonceliac gluten and/or wheat sensitivity. Increased gut permeability could explain the gluten/wheat effects in IBS patients. Finally, a GFD could improve symptoms in a subgroup of IBS patients. Conclusions: The possible interplay between IBS and gluten-related disorders represents a scientifically and clinically challenging issue. Further studies are needed to confirm these data and better clarify the involved pathophysiological mechanisms.

Download Full-text